Sandoz Group (OTCMKTS:SDZNY) Upgraded to Strong-Buy at The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of Sandoz Group (OTCMKTS:SDZNY) to a strong-buy rating in a research note released on Wednesday morning,Zacks.com reports.

Other analysts have also recently issued research reports about the company. Barclays cut Sandoz Group from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 26th. Jefferies Financial Group upgraded Sandoz Group from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 12th. Finally, Royal Bank Of Canada cut Sandoz Group from a “moderate buy” rating to a “hold” rating in a research note on Monday, March 23rd. Two analysts have rated the stock with a Strong Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy”.

Sandoz Group Price Performance

Shares of SDZNY opened at $80.29 on Wednesday. Sandoz Group has a 1-year low of $35.61 and a 1-year high of $94.15. The company’s fifty day moving average price is $81.58 and its 200-day moving average price is $72.60.

Sandoz Group Company Profile

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.